Orpathys approved in China for patients with lung cancer and MET gene alterations – AstraZeneca + HUTCHMED
AstraZeneca and HUTCHMED’s Orpathys (savolitinib) has been granted conditional approval in China to treat patients with non-small cell lung cancer (NSCLC) with MET exon 14 skipping alterations who… read more.
